Aspire Biopharma Warrant
ASBPW
34 hedge funds and large institutions have $536K invested in Aspire Biopharma Warrant in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
3% less funds holding
Funds holding: 35 → 34 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
35% less capital invested
Capital invested by funds: $823K → $536K (-$287K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPA
First Pacific Advisors
El Segundo,
California
|
+$1.11K |
| 2 |
FSI
Flow State Investments
Chicago,
Illinois
|
+$528 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
-$11.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.43K |
| 3 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$634 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
26
Atalaya Capital Management
New York
| $1.5K | – | – | – |
|
27
Walleye Capital
New York
| $1.4K | – | – | – |
|
|
MTCM
28
Mint Tower Capital Management
Amsterdam,
Netherlands
| $1K | – | – | – |
|
|
PMAM
29
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
FPA
30
First Pacific Advisors
El Segundo,
California
| $857 | +$1.11K | +28,482 | New |
|
31
Walleye Trading
New York
| $788 | – | – | – |
|
|
EFI
32
EHP Funds Inc
Toronto,
Canada
| $753 | – | – | – |
|
|
MC
33
Meteora Capital
Boca Raton,
Florida
| $753 | – | – | – |
|
|
OAC
34
OMERS Administration Corp
Toronto,
Ontario, Canada
| $752 | – | – | – |
|
|
PI
35
PEAK6 Investments
Chicago,
Illinois
| $376 | – | – | – |
|
|
SFM
36
Spartan Fund Management
Toronto, Ontario,
Canada
| – | -$11.2K | -187,080 | Closed |
|
|
37
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.43K | -23,803 | Closed |
|
|
BI
38
Bulldog Investors
Saddle Brook,
New Jersey
| – | -$634 | -12,500 | Closed |
|
ASBPW Hedge Fund Activity: Q1 2024 in Review
34 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2024, worth a combined $536K — down 35% from $823K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ASBPW and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was First Pacific Advisors, opening a new position worth an estimated $1.11K. The largest seller was Spartan Fund Management, exiting entirely with an estimated $11.2K sold.
- 34 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2024, down from 35 in Q4 2023.
- Funds reported $536K of Aspire Biopharma Warrant stock for Q1 2024, down 35% quarter-over-quarter.
- 3 funds opened new Aspire Biopharma Warrant positions in Q1 2024 and 4 closed out, a net change of -1 holder.
- The largest Aspire Biopharma Warrant buyer in Q1 2024 was First Pacific Advisors, an estimated $1.11K added.
- The largest Aspire Biopharma Warrant seller in Q1 2024 was Spartan Fund Management, an estimated $11.2K sold.
Based on aggregated 13F filings for Q1 2024.